Clinical trials: Lobular Breast Carcinoma
Breast Neoplasms, Carcinoma, Ductal, Breast
Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
A post-marketing study evaluating the transplantation of autologous fat augmented with Adipose Derived Regenerative Cells (ADRCs), in patients with functional and cosmetic breast deformities post segmental mastectomy or…
- Conditions
- Breast Neoplasms, Carcinoma, Ductal, Breast, Mammaplasty, Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,
- Trial name
- RESTORE-2 (NCT00616135)
- Testing
- ADRC-Enhanced Autologous Fat Transplant
- Where
- 5 sites in Belgium, Italy and 2 more
- Volunteers
- 71 people
- Sponsor
- Cytori Therapeutics
Breast Cancer
Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer
RATIONALE: Studying samples of nipple fluid, urine, and blood in the laboratory from patients with cancer and from patients at risk of developing cancer may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00897208
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Lobular Metastatic Breast Cancer
89Zr-atezolizumab PET Scan and Lobular Breast Cancer
The exploratory single center feasibility ImaGelato study is conducted as an imaging side study to the Dutch GELATO trial (Assessing efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer).
- Trial name
- ImaGelato (NCT04222426)
- Testing
- 89Zr-atezolizumab PET scans
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- University Medical Center Groningen
Breast Cancer
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer.
- Trial name
- NCT01349322
- Testing
- Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost
- Where
- 415 sites in United States, Canada and 6 more
- Volunteers
- 2,354 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
DCIS, Breast Carcinoma in Situ
The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS
The study hypothesis is that the rate of inadequate surgical margins after conservative breast surgery for DICS and the rate of reoperation (re-excision or/and mastectomy) is lower in the group of patients who underwent standard…
- Conditions
- DCIS, Breast Carcinoma in Situ, Calcification
- Trial name
- CEMinDCIS (NCT06217458)
- Testing
- Contrast Enhanced Mammography
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- Clinical Hospital Center Rijeka
Carcinoma, Ductal, Breast, Breast Cancer
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm
- Trial name
- NCT02983071
- Testing
- G1T38, Fulvestrant
- Where
- 8 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 102 people
- Sponsor
- G1 Therapeutics, Inc.
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Carcinoma
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Primary: To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer Secondary: Clinical response rate To investigate the safety of docetaxel doxorubicin…
- Trial name
- NCT00461344
- Testing
- Docetaxel, Doxorubicin
- Volunteers
- 20 people
- Sponsor
- Sanofi
Lobular Carcinoma, Breast Cancer
[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).
Invasive squamous cell carcinoma (ISCC) represents 5 to 15% of breast cancers. Despite the rarity of this pathology, the number of patients with Invasive squamous cell carcinoma treated at HCL is significant.
- Trial name
- FAPI-CL (NCT07313033)
- Testing
- [68]GA-FAPI-46 PET scan
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967239
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Volunteers
- 1,881 people, healthy volunteers welcome
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Endocrine Response in Women With Invasive Lobular Breast Cancer
RATIONALE: Currently, adjuvant endocrine therapy often follows a "one-size-fits- all" approach, with most premenopausal women receiving tamoxifen, and most postmenopausal receiving aromatase inhibitor therapy.
- Trial name
- NCT02206984
- Testing
- Tamoxifen, Anastrozole, Fulvestrant
- Where
- 12 sites in United States
- Volunteers
- 201 people
- Sponsor
- Priscilla McAuliffe
Breast Cancer, Ductal Carcinoma in Situ
Patient Outcomes from Second Film-readers and Test Threshold Relaxation in Breast Screening
Analysis of women's medical records to understand the impact of previous changes to breast cancer screening (increase from one to two clinicians examining each woman's mammograms, and what proportion of women they recall for…
- Trial name
- POSTBOx (NCT04365114)
- Testing
- Breast Screening Mammography with single reader, Breast screening mammography with two readers, Test threshold
- Where
- United Kingdom
- Volunteers
- 13,094,122 people, healthy volunteers welcome
- Sponsor
- University of Warwick
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer.
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Trial name
- NCT01219075
- Testing
- soy isoflavones, questionnaire administration, magnetic resonance imaging
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Breast Cancer
MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery
The purpose of this study is to show that addition of device use to a routine breast cancer tumor excision procedure is beneficial and assists the surgeon in correctly determining the extent of excision.
- Trial name
- Pivotal (NCT00749931)
- Testing
- MarginProbe, Lumpectomy
- Where
- 21 sites in United States, Israel
- Volunteers
- 664 people
- Sponsor
- Dune Medical Devices
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Endometrial Cancer
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen.
- Trial name
- NCT00002920
- Testing
- medroxyprogesterone, tamoxifen citrate, adjuvant therapy
- Where
- 122 sites in United States
- Volunteers
- 313 people
- Sponsor
- SWOG Cancer Research Network
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers.
- Conditions
- Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
- Trial name
- NCT05919108
- Testing
- Endocrine Therapy, Biopsy of breast, Neratinib
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Tubular Breast Cancer, Mucinous Breast Cancer
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
- Trial name
- SHPD001 (NCT02199418)
- Testing
- Paclitaxel, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- RenJi Hospital
Metastatic Breast Cancer, Lobular Breast Carcinoma
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response…
- Trial name
- NCT05964504
- Testing
- Blood Specimen
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Francisco